

<b>PTO/SB/08A</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/843,132
				Filing Date	April 25, 2001
				Confirmation Number	8349
				First Named Inventor	John P. McKearn et al.
				Group Art Unit	1614
				Examiner Name	Rebecca Cook
Sheet	1	of	2	Attorney Docket No.	PHA 2004 (3167/12/US)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
<i>h</i>	44.	6,077,850		Carter et al.	06-20-2000
<i>h</i>	45.	6,087,392		Reiter	07-11-2000
<i>h</i>	46.	6,110,964		Robinson	08-29-2000
<i>h</i>	47.	6,114,361		Robinson et al.	09-05-2000
<i>h</i>	48.	6,156,798		Reiter	12-05-2000
<i>h</i>	49.	6,214,870	B1	McClure et al.	04-10-2001
<i>h</i>	50.	6,277,878	B1	Nakao et al.	08-21-2001
<i>h</i>	51.	6,294,558	B1	Ando et al.	09-25-2001
<i>h</i>	52.	6,303,628	B1	Nakao et al.	10-16-2001

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
<i>h</i>	53.	EP	1 081 137	A1	Pfizer Products Inc.	03-07-2001	
<i>h</i>	54.	EP	1 088 550	A1	Pfizer Products Inc.	04-04-2001	

Examiner Signature	<i>h</i>	Date Considered	7/10/04
--------------------	----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<b>PTO/SB/08A</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/843,132
				Filing Date	April 25, 2001
				Confirmation Number	8349
				First Named Inventor	John P. McKearn et al.
				Group Art Unit	1614
				Examiner Name	Rebecca Cook
Sheet	2	of	2	Attorney Docket No.	PHA 2004 (3167/12/US)

N	55.	EP	1 104 759	A1	Pfizer Products Inc.	06-06-2001	
N	56.	EP	1 104 760	A1	Pfizer Products Inc.	06-06-2001	
N	57.	EP	1 134 215	A1	Pfizer Products Inc.	09-19-2001	
N	58.	EP	1 138 680	A1	Pfizer Products Inc.	10-04-2001	
N	59.	WO	97/20824	A1	Agouron Pharmaceuticals, Inc.	06-12-1997	
N	60.	WO	98/03516	A1	Pfizer Inc.	01-29-1998	
N	61.	WO	98/30566	A1	Pfizer Inc.	07-16-1998	
N	62.	WO	98/47890	A1	G.D. Searle & Co.	10-29-1998	
N	63.	WO	99/21583	A1	Warner-Lambert Company	05-06-1999	
N	64.	WO	00/09485	A1	Pfizer Products Inc.	02-24-2000	
N	65.	WO	00/09492	A1	Pfizer Products Inc.	02-24-2000	
N	66.	WO	00/73294	A2	Pfizer Products Inc.	12-07-2000	
N	67.	WO	01/12611	A1	Pfizer Products Inc.	02-22-2001	
N	68.	WO	01/40216	A1	Pfizer Products Inc.	06-07-2001	

#### OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
N	69.	TRIFAN, O.C., et al., Cyclooxygenase-2 Inhibition with Celecoxib Enhances Antitumor Efficacy and Reduces Diarrhea Side Effect of CPT-11, Cancer Research, Oct. 15, 2002, pp. 5778-84, Vol. 62, No. 20	

Examiner Signature	<i>N Cook</i>	Date Considered	7/10/04
--------------------	---------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.